^{Original article from Fortune by Naomi Kresge and Bloomberg}

Patients who took the diet drug Wegovy for a year had a reduced risk of heart disease in an early hint that Novo Nordisk’s best-selling obesity medicine may also have a positive impact on cardiovascular health.

People followed in a study saw their 10-year risk of cardiovascular disease decline by 18%, said Andres Acosta, an associate professor of medicine at the Mayo Clinic. Researchers used a standardized survey of heart risk to assess about 100 people, mostly White women, who took Wegovy over the course of a year at clinic sites around the US.

The study took place in the real world rather than a clinical trial, meaning there was no control group, so research…